In platinum-resistant ovarian cancer patients treated with niraparib and pembrolizumab, Färkkilä et al. identified the presence of a mutational signature (surrogate of HR deficiency) and/or the presence of IFN-primed exhausted effector CD8 T cells in the TME, to be associated with prolonged progression-free survival. Here, CD8A is linked to ovarian cancer.